Linda S Wicker

List of Publications by Year
in descending order

131 papers	11,914 citations	36271 51 h-index	28275 105 g-index
139 all docs	139 docs citations	139 times ranked	11672 citing authors

#	Article	IF	Citations
1	Circulating C-Peptide Levels in Living Children and Young People and Pancreatic Î²-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration. Diabetes, 2022, 71, 1591-1596.	0.3	12
2	Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. Nature Genetics, 2021, 53, 962-971.	9.4	133
3	Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus. Wellcome Open Research, 2021, 6, 149.	0.9	6
4	Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73. Communications Biology, 2021, 4, 1186.	2.0	19
5	Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic Î²-Cells. Diabetes Care, 2020, 43, 169-177.	4.3	60
6	Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Medicine, 2020, 12, 55.	3.6	61
7	Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial. Wellcome Open Research, 2020, 5, 49.	0.9	16
8	Stochastic search and joint fine-mapping increases accuracy and identifies previously unreported associations in immune-mediated diseases. Nature Communications, 2019, 10, 3216.	5.8	24
9	Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice. PLoS Genetics, 2019, 15, e1008178.	1.5	8
10	Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression. Frontiers in Immunology, 2019, 10, 2606.	2.2	31
11	A Novel <i>Pkhd1</i> Mutation Interacts with the Nonobese Diabetic Genetic Background To Cause Autoimmune Cholangitis. Journal of Immunology, 2018, 200, 147-162.	0.4	10
12	A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. Journal of Autoimmunity, 2018, 95, 1-14.	3.0	129
13	The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Research and Therapy, 2018, 20, 152.	1.6	36
14	The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. JCI Insight, 2018, 3, .	2.3	29
15	In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment. Data in Brief, 2017, 12, 676-691.	0.5	8
16	Human IL-6R hi TIGIT âˆ’ CD4 + CD127 low CD25 + T cells display potent in vitro suppressive capacity and a distinct Th17 profile. Clinical Immunology, 2017, 179, 25-39.	1.4	27
17	Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity. Journal of Autoimmunity, 2017, 84, 75-86.	3.0	78
18	Chromosome contacts in activated T cells identify autoimmune disease candidate genes. Genome Biology, 2017, 18, 165.	3.8	68

#	Article	IF	Citations
19	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. JCI Insight, 2017, 2, .	2.3	46
20	Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. Wellcome Open Research, 2017, 2, 28.	0.9	14
21	Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. PLoS Medicine, 2016, 13, e1002139.	3.9	117
22	Epigenetic analysis of regulatory T cells using multiplex bisulfite sequencing. European Journal of Immunology, 2015, 45, 3200-3203.	1.6	26
23	Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. BMJ Open, 2015, 5, e009799.	0.8	20
24	Dissection of a Complex Disease Susceptibility Region Using a Bayesian Stochastic Search Approach to Fine Mapping. PLoS Genetics, 2015, 11, e1005272.	1.5	55
25	IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia, 2015, 58, 781-790.	2.9	116
26	Sustained inÂvivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. Journal of Autoimmunity, 2015, 56, 66-80.	3.0	87
27	Genome-Wide Transcriptional Analyses of Islet-Specific CD4+ T Cells Identify Idd9 Genes Controlling Diabetogenic T Cell Function. Journal of Immunology, 2015, 194, 2654-2663.	0.4	3
28	Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes. Diabetes, 2015, 64, 3891-3902.	0.3	46
29	Ptpn22 and Cd2 Variations Are Associated with Altered Protein Expression and Susceptibility to Type 1 Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2015, 195, 4841-4852.	0.4	10
30	Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles. Journal of Immunology, 2014, 193, 889-900.	0.4	30
31	Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open, 2014, 4, e005559-e005559.	0.8	33
32	Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes. PLoS ONE, 2014, 9, e89561.	1.1	54
33	A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes. Diabetes, 2014, 63, 2538-2550.	0.3	261
34	Fine mapping of type 1 diabetes regions Idd9.1 and Idd9.2 reveals genetic complexity. Mammalian Genome, 2013, 24, 358-375.	1.0	13
35	Postthymic Expansion in Human CD4 Naive T Cells Defined by Expression of Functional High-Affinity IL-2 Receptors. Journal of Immunology, 2013, 190, 2554-2566.	0.4	60
36	Genetic Interactions among <i>Idd3</i>, <i>Idd5.1</i>, <i>Idd5.2</i>, and <i>Idd5.3</i> Protective Loci in the Nonobese Diabetic Mouse Model of Type 1 Diabetes. Journal of Immunology, 2013, 190, 3109-3120.	0.4	16

#	Article	IF	Citations
37	The B10 <i>Idd9.3</i> Locus Mediates Accumulation of Functionally Superior CD137+ Regulatory T Cells in the Nonobese Diabetic Type 1 Diabetes Model. Journal of Immunology, 2012, 189, 5001-5015.	0.4	36
38	Overexpression of the CTLA-4 Isoform Lacking Exons 2 and 3 Causes Autoimmunity. Journal of Immunology, 2012, 188, 155-162.	0.4	25
39	Type 1 Diabetes-Associated <i>IL2RA</i> Variation Lowers IL-2 Signaling and Contributes to Diminished CD4+CD25+ Regulatory T Cell Function. Journal of Immunology, 2012, 188, 4644-4653.	0.4	187
40	PTPN22 Alters the Development of Regulatory T Cells in the Thymus. Journal of Immunology, 2012, 188, 5267-5275.	0.4	99
41	Cellular Mechanisms of Restored Â-Cell Tolerance Mediated by Protective Alleles of Idd3 and Idd5. Diabetes, 2012, 61, 166-174.	0.3	7
42	B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3c4 model of autoimmune cholangitis. Cellular Immunology, 2011, 268, 16-23.	1.4	22
43	The Soluble CTLA-4 Splice Variant Protects From Type 1 Diabetes and Potentiates Regulatory T-Cell Function. Diabetes, 2011, 60, 1955-1963.	0.3	79
44	CD8 T Cells Mediate Direct Biliary Ductule Damage in Nonobese Diabetic Autoimmune Biliary Disease. Journal of Immunology, 2011, 186, 1259-1267.	0.4	44
45	Evidence that<i>Cd101</i>Is an Autoimmune Diabetes Gene in Nonobese Diabetic Mice. Journal of Immunology, 2011, 187, 325-336.	0.4	26
46	Identification of <i>Cd101</i> as a Susceptibility Gene for <i>Novosphingobium aromaticivorans</i>-Induced Liver Autoimmunity. Journal of Immunology, 2011, 187, 337-349.	0.4	30
47	Multiplexed immunophenotyping of human antigen-presenting cells in whole blood by polychromatic flow cytometry. Nature Protocols, 2010, 5, 357-370.	5.5	27
48	<i>Idd9.1</i>Locus Controls the Suppressive Activity of FoxP3+CD4+CD25+ Regulatory T-Cells. Diabetes, 2010, 59, 272-281.	0.3	31
49	<i>Idd9.2</i>and<i>Idd9.3</i>Protective Alleles Function in CD4+ T-Cells and Nonlymphoid Cells to Prevent Expansion of Pathogenic Islet-Specific CD8+ T-Cells. Diabetes, 2010, 59, 1478-1486.	0.3	24
50	Nonobese Diabetic Congenic Strain Analysis of Autoimmune Diabetes Reveals Genetic Complexity of the Idd18 Locus and Identifies Vav3 as a Candidate Gene. Journal of Immunology, 2010, 184, 5075-5084.	0.4	29
51	Genome-wide end-sequenced BAC resources for the NOD/MrkTacâ˜† and NOD/ShiLtJâ˜†â˜† mouse genomes. Genomics, 2010, 95, 105-110.	1.3	14
52	Idd Loci Synergize to Prolong Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice. Diabetes, 2009, 58, 165-173.	0.3	14
53	Genetic Evidence That the Differential Expression of the Ligand-Independent Isoform of CTLA-4 Is the Molecular Basis of the <i>Idd5.1</i> Type 1 Diabetes Region in Nonobese Diabetic Mice. Journal of Immunology, 2009, 183, 5146-5157.	0.4	65
54	Expression of Diabetes-Associated Genes by Dendritic Cells and CD4 T Cells Drives the Loss of Tolerance in Nonobese Diabetic Mice. Journal of Immunology, 2009, 183, 1533-1541.	0.4	33

#	Article	IF	Citations
55	Amino acid polymorphisms altering the glycosylation of IL-2 do not protect from type 1 diabetes in the NOD mouse. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11236-11240.	3.3	12
56	IL2RA Genetic Heterogeneity in Multiple Sclerosis and Type 1 Diabetes Susceptibility and Soluble Interleukin-2 Receptor Production. PLoS Genetics, 2009, 5, e1000322.	1.5	210
57	Slc11a1 Enhances the Autoimmune Diabetogenic T-Cell Response by Altering Processing and Presentation of Pancreatic Islet Antigens. Diabetes, 2009, 58, 156-164.	0.3	39
58	Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nature Genetics, 2009, 41, 1011-1015.	9.4	249
59	IL-2 and its high-affinity receptor: Genetic control of immunoregulation and autoimmunity. Seminars in Immunology, 2009, 21, 363-371.	2.7	52
60	The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice. Journal of Clinical Immunology, 2008, 28, 685-696.	2.0	62
61	Chapter 6 Geneâ€"Gene Interactions in the NOD Mouse Model of Type 1 Diabetes. Advances in Immunology, 2008, 100, 151-175.	1.1	65
62	Liver Autoimmunity Triggered by Microbial Activation of Natural Killer T Cells. Cell Host and Microbe, 2008, 3, 304-315.	5.1	219
63	Genome-Wide Microarray Expression Analysis of CD4+ T Cells from Nonobese Diabetic Congenic Mice Identifies <i>Cd55</i> (<i>Daf1</i>) and <i>Acadl</i> as Candidate Genes for Type 1 Diabetes. Journal of Immunology, 2008, 180, 1071-1079.	0.4	21
64	NKG2D-RAE-1 Receptor-Ligand Variation Does Not Account for the NK Cell Defect in Nonobese Diabetic Mice. Journal of Immunology, 2008, 181, 7073-7080.	0.4	12
65	Commonality in the genetic control of TypeÂ1 diabetes in humans and NOD mice: variants of genes in the IL-2 pathway are associated with autoimmune diabetes in both species. Biochemical Society Transactions, 2008, 36, 312-315.	1.6	26
66	Natural Genetic Variants Influencing Type 1 Diabetes in Humans and in the NOD Mouse. Novartis Foundation Symposium, 2008, 267, 57-75.	1.2	6
67	Allelic variant in<i>CTLA4</i>alters T cell phosphorylation patterns. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18607-18612.	3.3	57
68	Interactions between <i>Idd5.1/Ctla4</i> and Other Type 1 Diabetes Genes. Journal of Immunology, 2007, 179, 8341-8349.	0.4	54
69	Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nature Genetics, 2007, 39, 329-337.	9.4	333
70	Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nature Genetics, 2007, 39, 857-864.	9.4	1,324
71	Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nature Genetics, 2007, 39, 1074-1082.	9.4	380
72	New tools for defining the 'genetic background' of inbred mouse strains. Nature Immunology, 2007, 8, 669-673.	7.0	27

#	Article	IF	Citations
73	The Use of Idd Congenic Mice to Identify Checkpoints of Peripheral Tolerance to Islet Antigen. Annals of the New York Academy of Sciences, 2007, 1103, 118-127.	1.8	11
74	In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. Nature Genetics, 2006, 38, 479-483.	9.4	118
75	A 20-Mb Region of Chromosome 4 Controls TNF-Î±-Mediated CD8+ T Cell Aggression Toward Î² Cells in Type 1 Diabetes. Journal of Immunology, 2006, 177, 5105-5114.	0.4	9
76	NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. Journal of Experimental Medicine, 2006, 203, 1209-1219.	4.2	173
77	Genes within the Idd5 and Idd9/11 Diabetes Susceptibility Loci Affect the Pathogenic Activity of B Cells in Nonobese Diabetic Mice. Journal of Immunology, 2006, 177, 7033-7041.	0.4	29
78	Genetic susceptibility to type 1 diabetes. Current Opinion in Immunology, 2005, 17, 601-608.	2.4	108
79	CD8+ T Cell Tolerance in Nonobese Diabetic Mice Is Restored by Insulin-Dependent Diabetes Resistance Alleles. Journal of Immunology, 2005, 175, 1677-1685.	0.4	33
80	Autoimmune Diabetes and Resistance to Xenograft Transplantation Tolerance in NOD Mice. Diabetes, 2005, 54, 107-115.	0.3	24
81	Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes. Journal of Autoimmunity, 2005, 25, 13-20.	3.0	54
82	Type 1 diabetes genes and pathways shared by humans and NOD mice. Journal of Autoimmunity, 2005, 25, 29-33.	3.0	145
83	Fine Mapping, Gene Content, Comparative Sequencing, and Expression Analyses Support<i>Ctla4</i>and<i>Nramp1</i>as Candidates for<i>Idd5.1</i>and<i>Idd5.2</i>in the Nonobese Diabetic Mouse. Journal of Immunology, 2004, 173, 164-173.	0.4	102
84	Genetic Control of Autoimmunity: Protection from Diabetes, but Spontaneous Autoimmune Biliary Disease in a Nonobese Diabetic Congenic Strain. Journal of Immunology, 2004, 173, 2315-2323.	0.4	88
85	The Diabetes Susceptibility Locus Idd5.1 on Mouse Chromosome 1 Regulates ICOS Expression and Modulates Murine Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2004, 173, 157-163.	0.4	57
86	Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice Is Controlled by Allelic Variants of Idd3. Diabetes, 2004, 53, 1972-1978.	0.3	21
87	An Autoimmune Disease-Associated CTLA-4 Splice Variant Lacking the B7 Binding Domain Signals Negatively in T Cells. Immunity, 2004, 20, 563-575.	6.6	197
88	Genetic separation of the transplantation tolerance and autoimmune phenotypes in NOD mice. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 255-261.	2.6	4
89	Islet Cell Autoimmunity and Transplantation Tolerance: Two Distinct Mechanisms?. Annals of the New York Academy of Sciences, 2003, 1005, 148-156.	1.8	25
90	Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 2003, 423, 506-511.	13.7	1,980

#	Article	IF	Citations
91	Insulin Autoantibodies Are Associated With Islet Inflammation But Not Always Related to Diabetes Progression in NOD Congenic Mice. Diabetes, 2003, 52, 882-886.	0.3	47
92	Identification of a Structurally Distinct CD101 Molecule Encoded in the 950-kb Idd10 Region of NOD Mice. Diabetes, 2003, 52, 1551-1556.	0.3	27
93	The Derivation of Highly Germline-Competent Embryonic Stem Cells Containing NOD-Derived Genome. Diabetes, 2003, 52, 205-208.	0.3	47
94	Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. Journal of Leukocyte Biology, 2003, 73, 771-780.	1.5	146
95	NOD Congenic Mice Genetically Protected From Autoimmune Diabetes Remain Resistant to Transplantation Tolerance Induction. Diabetes, 2003, 52, 321-326.	0.3	52
96	Genetic Disassociation of Autoimmunity and Resistance to Costimulation Blockade-Induced Transplantation Tolerance in Nonobese Diabetic Mice. Journal of Immunology, 2003, 171, 185-195.	0.4	67
97	Photochemical preparation of a pyridone containing tetracycle: A jak protein kinase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1219-1223.	1.0	263
98	Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: the NOD model of type 1 diabetes. Genome Research, 2002, 12, 232-43.	2.4	81
99	Genetic Protection from the Inflammatory Disease Type 1 Diabetes in Humans and Animal Models. Immunity, 2001, 15, 387-395.	6.6	186
100	The murine type 1 diabetes loci, Idd1, Idd3, Idd5, Idd9, and Idd17/10/18, do not control thymic CD4 â˘' CD8 â˘' /TCRÎ±Î² + deficiency in the nonobese diabetic mouse. Mammalian Genome, 2001, 12, 175-176.	1.0	8
101	Statistical Modeling of Interlocus Interactions in a Complex Disease: Rejection of the Multiplicative Model of Epistasis in Type 1 Diabetes. Genetics, 2001, 158, 357-367.	1.2	72
102	Congenic Mapping of the Type 1 Diabetes Locus, Idd3, to a 780-kb Region of Mouse Chromosome 3: Identification of a Candidate Segment of Ancestral DNA by Haplotype Mapping. Genome Research, 2000, 10, 446-453.	2.4	126
103	DIFFERENTIAL GLYCOSYLATION OF INTERLEUKIN 2, THE MOLECULAR BASIS FOR THE NOD Idd3 TYPE 1 DIABETES GENE?. Cytokine, 2000, 12, 477-482.	1.4	66
104	The NOD Idd9 Genetic Interval Influences the Pathogenicity of Insulitis and Contains Molecular Variants of Cd30, Tnfr2, and Cd137. Immunity, 2000, 13, 107-115.	6.6	153
105	Tetrapeptide derived inhibitors of complexation of a class II MHC: the peptide backbone is not inviolate. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2109-2114.	1.0	4
106	QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. Nature Genetics, 1999, 21, 158-160.	9.4	127
107	Major Histocompatibility Complexâ€"linked Control of Autoimmunity. Journal of Experimental Medicine, 1997, 186, 973-975.	4.2	43
108	SAR for MHC class II binding tetrapeptides: Correlation with potential binding site. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 19-24.	1.0	9

#	Article	IF	Citations
109	Autoimmunity. Current Opinion in Immunology, 1995, 7, 783-785.	2.4	7
110	Responses of NOD Congenic Mice to a Glutamic Acid Decarboxylase-derived Peptide. Journal of Autoimmunity, 1994, 7, 635-641.	3.0	26
111	Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK 506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771.. Journal of Antibiotics, 1992, 45, 118-123.	1.0	23
112	Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by Actinomycete sp. ATCC 53828.. Journal of Antibiotics, 1992, 45, 577-580.	1.0	6
113	Acquired allo-tolerance to major or minor histocompatibility antigens indifferently contributes to preventing diabetes development in non-obese diabetic (NOD) mice. Journal of Autoimmunity, 1992, 5, 591-601.	3.0	9
114	Linkage analysis of 84 microsatellite markers in intra- and interspecific backcrosses. Mammalian Genome, 1992, 3, 457-460.	1.0	19
115	Genetic analysis of autoimmune type 1 diabetes mellitus in mice. Nature, 1991, 351, 542-547.	13.7	513
116	Type 1 diabetes in mice is linked to the interleukin-1 receptor and Lsh/Ity/Bcg genes on chromosome 1. Nature, 1991, 353, 262-265.	13.7	181
117	THE ROLE OF CD4+ HELPER T CELLS IN THE DESTRUCTION OF MICROENCAPSULATED ISLET XENOGRAFTS IN NOD MICE. Transplantation, 1990, 49, 396-403.	0.5	122
118	Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. European Journal of Immunology, 1990, 20, 2277-2283.	1.6	151
119	5-Halo-6-phenyl pyrimidinones and 8-substituted guanosines: Biological response modifiers with similar effects on B cells. Cellular Immunology, 1988, 112, 156-165.	1.4	11
120	MHC-Linked Diabetogenic Gene in the NOD Mouse Is Not Absolutely Recessive. Annals of the New York Academy of Sciences, 1988, 546, 240-241.	1.8	1
121	Large, activated B cells are the primary B-cell target of 8-bromoguanosine and 8-mercaptoguanosine. Cellular Immunology, 1987, 106, 318-329.	1.4	20
122	Regulation of T15 idiotype dominance. Cellular Immunology, 1986, 100, 570-576.	1.4	4
123	Immunodominant protein epitopes I. Induction of suppression to hen egg white lysozyme is obliterated by removal of the first three N-terminal amino acids. European Journal of Immunology, 1984, 14, 442-447.	1.6	58
124	Immunodominant protein epitopes II. The primary antibody response to hen egg white lysozyme requires and focuses upon a unique N-terminal epitope. European Journal of Immunology, 1984, 14, 447-453.	1.6	25
125	The Design of Regulatory Circuitry: Predominant Idiotypy and the Idea of Regulatory Parsimony. Annals of the New York Academy of Sciences, 1983, 418, 198-205.	1.8	8
126	Immunological focusing by the mouse major histocompatibility complex: Mouse strains confronted with distantly related lysozymes confine their attention to very few epitopes. European Journal of Immunology, 1982, 12, 535-540.	1.6	74

#	Article	IF	Citations
127	Two distinct high immune response phenotypes are both controlled byH-2 genes mapping inK orI-A. Immunogenetics, 1981, 12, 253-265.	1.2	18
128	Hierarchy ofH-2 haplotypes governs inheritance of immune responsiveness to TNP-MSA. Immunogenetics, 1980, 10, 235-246.	1.2	6
129	Genetic Control of Susceptibility to <i>Cryptococcus neoformans</i> in Mice. Infection and Immunity, 1980, 29, 494-499.	1.0	131
130	Resistance ofH-2 heterozygous mice to parental tumors. Immunogenetics, 1977, 4, 601-607.	1.2	80
131	Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. Wellcome Open Research, 0, 2, 28.	0.9	6